FDA Fully Approves First Complement Inhibitor to Slow Kidney Decline in IgA Nephropathy
Iptacopan cut the rate of kidney function decline by 48% over two years in a phase III trial, earning full FDA approval for IgAN.
Summary
The FDA has granted full approval to iptacopan (Fabhalta), the first complement inhibitor cleared for IgA nephropathy (IgAN), a common autoimmune kidney disease. The drug works by blocking the alternative complement pathway, a key driver of kidney inflammation. In the phase III APPLAUSE-IgAN trial, iptacopan slowed kidney function decline by 48% compared to placebo over 24 months. This matters because roughly half of IgAN patients progress to kidney failure or death within 10 to 20 years of diagnosis. The approval upgrades iptacopan from accelerated to traditional status, signaling confirmed clinical benefit rather than just a surrogate marker like protein in urine. It joins two other fully approved IgAN therapies, expanding treatment options for a disease that has historically had few targeted interventions.
Detailed Summary
IgA nephropathy is one of the most common autoimmune kidney diseases worldwide, affecting an estimated 2.5 per 100,000 adults annually. It occurs when abnormal IgA antibodies accumulate and damage the kidney's filtering units, leading to inflammation, protein leakage into urine, and eventually end-stage renal disease. Approximately half of diagnosed patients — most of whom are identified in young adulthood — progress to kidney failure or death within 10 to 20 years. Until recently, treatment options were limited and largely non-specific.
Iptacopan, developed by Novartis under the brand name Fabhalta, is a first-in-class Factor B inhibitor that selectively targets the alternative complement pathway. This pathway is one of the primary mechanisms driving glomerular inflammation in IgAN. By blocking Factor B, iptacopan interrupts the cascade of immune activity that damages kidney tissue, addressing root disease biology rather than just managing symptoms.
The FDA's full approval was based on results from the phase III APPLAUSE-IgAN trial. Over 24 months, patients on iptacopan experienced an annualized eGFR decline of -3 mL/min/1.73 m² per year, compared to -5.7 mL/min/1.73 m² per year in the placebo group — a 48% reduction in the rate of kidney function loss. Importantly, the benefit was consistent across all prespecified patient subgroups, suggesting broad applicability.
For health-conscious adults and clinicians, this approval is significant because eGFR — a measure of how well kidneys filter blood — is a direct biomarker of kidney health and longevity risk. Slowing its decline meaningfully extends the window before dialysis or transplant becomes necessary, preserving quality of life and potentially years of healthy function.
Caveats include a boxed warning for infections caused by encapsulated bacteria, requiring vaccinations before starting treatment. The drug is only available through a restricted risk mitigation program. Common side effects include abdominal pain, dizziness, and nausea. Long-term safety data beyond the trial window remain to be established, and real-world effectiveness may differ from controlled trial conditions.
Key Findings
- Iptacopan reduced the rate of kidney function decline by 48% versus placebo over 24 months in IgAN patients.
- eGFR decline slowed to -3 vs -5.7 mL/min/1.73 m² per year, a clinically meaningful preservation of kidney function.
- Iptacopan is the first Factor B inhibitor approved for IgAN, targeting the alternative complement pathway directly.
- Benefit was consistent across all patient subgroups, supporting broad use in the IgAN population.
- Drug carries a boxed warning for encapsulated bacterial infections; vaccination required before starting treatment.
Methodology
This is a news report from MedPage Today summarizing an FDA approval announcement and phase III trial results. The source is a credible medical news outlet targeting clinicians. Evidence is based on the APPLAUSE-IgAN phase III randomized controlled trial with a 24-month endpoint, considered a high-quality evidence standard.
Study Limitations
The article is a news summary and does not provide full trial data, including patient numbers, baseline characteristics, or detailed subgroup analyses. Long-term safety beyond 24 months is not yet established. Real-world outcomes may differ from the controlled trial setting and require post-marketing surveillance confirmation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: